Photo of Mission Therapeutics
2 known investors
Mission Therapeutics develops first-in-class small molecule inhibitors of deubiquitylating enzymes (DUBs) as therapeutics for serious diseases including Parkinson's and other neurodegenerative conditions, heart and kidney disease, fibrosis, and rare mitochondrial diseases. Its lead candidates, MTX325 and MTX652, aim to inhibit the USP30 enzyme involved in the cellular quality control process of mitophagy.